{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:12:29Z","timestamp":1770973949381,"version":"3.50.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tianjin University of Traditional Chinese Medicine Startup Funding"},{"name":"Open Projects Fund of Shandong Key Laboratory of Carbohydrate Chemistry and Glycobiology, Shandong University","award":["2023CCG13"],"award-info":[{"award-number":["2023CCG13"]}]},{"name":"Jilin Province Science and Technology Development Plan Item","award":["YDZJ202501ZYTS818"],"award-info":[{"award-number":["YDZJ202501ZYTS818"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-026"],"award-info":[{"award-number":["2021-I2M-1-026"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-025-03425-8","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T01:34:14Z","timestamp":1747791254000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Co-encapsulation of norcantharidin prodrugs and lomitapide in nanoparticles to regulate CCL4 expression by inhibiting Wnt\/\u03b2-catenin pathway for improved anti-tumor immunotherapy"],"prefix":"10.1186","volume":"23","author":[{"given":"Feng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manqing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"3425_CR1","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231\u20135.","journal-title":"Nature"},{"key":"3425_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger S, Dai D, Horton B, Gajewski TF. Tumor-Residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31:711\u2013e723714.","journal-title":"Cancer Cell"},{"key":"3425_CR3","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","volume":"54","author":"AJ Ozga","year":"2021","unstructured":"Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity. 2021;54:859\u201374.","journal-title":"Immunity"},{"key":"3425_CR4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/acel.12294","volume":"14","author":"NL Cheng","year":"2015","unstructured":"Cheng NL, Chen X, Kim J, Shi AH, Nguyen C, Wersto R, Weng NP. MicroRNA-125b modulates inflammatory chemokine CCL4 expression in immune cells and its reduction causes CCL4 increase with age. Aging Cell. 2015;14:200\u20138.","journal-title":"Aging Cell"},{"key":"3425_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nri1862","volume":"6","author":"K Honey","year":"2006","unstructured":"Honey K. CCL3 and CCL4 actively recruit CD8\u2009+\u2009T cells. Nat Rev Immunol. 2006;6:427\u2013427.","journal-title":"Nat Rev Immunol"},{"key":"3425_CR6","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/ni735","volume":"2","author":"RS Bystry","year":"2001","unstructured":"Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG. B cells and professional apcs recruit regulatory T cells via CCL4. Nat Immunol. 2001;2:1126\u201332.","journal-title":"Nat Immunol"},{"key":"3425_CR7","first-page":"3565","volume":"10","author":"J-Q Liu","year":"2020","unstructured":"Liu J-Q, Zhu J, Hu A, Zhang A, Yang C, Yu J, Ghoshal K, Basu S, Bai X-F. Is AAV-delivered IL-27 a potential immunotherapeutic for cancer? Am J Cancer Res. 2020;10:3565.","journal-title":"Am J Cancer Res"},{"key":"3425_CR8","first-page":"1693","volume":"147","author":"BD Car","year":"1995","unstructured":"Car BD, Eng VM, Schnyder B, LeHir M, Shakhov AN, Woerly G, Huang S, Aguet M, Anderson TD, Ryffel B. Role of interferon-gamma in Interleukin 12-induced pathology in mice. Am J Pathol. 1995;147:1693.","journal-title":"Am J Pathol"},{"key":"3425_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1006\/clin.1996.4306","volume":"83","author":"B Ryffel","year":"1997","unstructured":"Ryffel B. Interleukin-12: role of interferon-\u03b3 in IL-12 adverse effects. Clin Immunol Immunopathol. 1997;83:18\u201320.","journal-title":"Clin Immunol Immunopathol"},{"key":"3425_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00262-014-1523-1","volume":"63","author":"W Lasek","year":"2014","unstructured":"Lasek W, Zago\u017cd\u017con R, Jakobisiak M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother. 2014;63:419\u201335.","journal-title":"Cancer Immunol Immunother"},{"key":"3425_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/med.21530","volume":"39","author":"J Yang","year":"2019","unstructured":"Yang J, Hu L. Immunomodulators targeting the PD-1\/PD\u2010L1 protein\u2010protein interaction: from antibodies to small molecules. Med Res Rev. 2019;39:265\u2013301.","journal-title":"Med Res Rev"},{"key":"3425_CR12","doi-asserted-by":"publisher","first-page":"113821","DOI":"10.1016\/j.bcp.2020.113821","volume":"174","author":"C Bailly","year":"2020","unstructured":"Bailly C, Vergoten G. Protein homodimer sequestration with small molecules: focus on PD-L1. Biochem Pharmacol. 2020;174:113821.","journal-title":"Biochem Pharmacol"},{"key":"3425_CR13","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nchembio.2360","volume":"13","author":"GI Vladimer","year":"2017","unstructured":"Vladimer GI, Snijder B, Krall N, Bigenzahn JW, Huber KV, Lardeau C-H, Sanjiv K, Ringler A, Berglund UW, Sabler M. Global survey of the Immunomodulatory potential of common drugs. Nat Chem Biol. 2017;13:681\u201390.","journal-title":"Nat Chem Biol"},{"key":"3425_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrd4596","volume":"14","author":"JL Adams","year":"2015","unstructured":"Adams JL, Smothers J, Srinivasan R, Hoos A. Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discovery. 2015;14:603\u201322.","journal-title":"Nat Rev Drug Discovery"},{"key":"3425_CR15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31:711\u201323. e714.","journal-title":"Cancer Cell"},{"key":"3425_CR16","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1016\/j.ymthe.2018.09.005","volume":"26","author":"S Ganesh","year":"2018","unstructured":"Ganesh S, Shui X, Craig KP, Park J, Wang W, Brown BD, Abrams MT. RNAi-mediated \u03b2-catenin Inhibition promotes T cell infiltration and antitumor activity in combination with immune checkpoint Blockade. Mol Ther. 2018;26:2567\u201379.","journal-title":"Mol Ther"},{"key":"3425_CR17","first-page":"116","volume-title":"Beta-catenin inhibitors in cancer immunotherapy","author":"T Gajewski","year":"2016","unstructured":"Gajewski T, Spranger S. Beta-catenin inhibitors in cancer immunotherapy. USA: The University of Chicago; 2016. p. 116."},{"key":"3425_CR18","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1074\/jbc.274.6.3439","volume":"274","author":"W Hsu","year":"1999","unstructured":"Hsu W, Zeng L, Costantini F. Identification of a domain of Axin that binds to the serine\/threonine protein phosphatase 2A and a self-binding domain. J Biol Chem. 1999;274:3439\u201345.","journal-title":"J Biol Chem"},{"key":"3425_CR19","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1126\/science.283.5410.2089","volume":"283","author":"JM Seeling","year":"1999","unstructured":"Seeling JM, Miller JR, Gil R, Moon RT, White R, Virshup DM. Regulation of \u03b2-catenin signaling by the B56 subunit of protein phosphatase 2A. Science. 1999;283:2089\u201391.","journal-title":"Science"},{"key":"3425_CR20","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/sj.emboj.7601607","volume":"26","author":"W Luo","year":"2007","unstructured":"Luo W, Peterson A, Garcia BA, Coombs G, Kofahl B, Heinrich R, Shabanowitz J, Hunt DF, Yost HJ, Virshup DM. Protein phosphatase 1 regulates assembly and function of the \u03b2-catenin degradation complex. EMBO J. 2007;26:1511\u201321.","journal-title":"EMBO J"},{"key":"3425_CR21","doi-asserted-by":"publisher","first-page":"a007898","DOI":"10.1101\/cshperspect.a007898","volume":"5","author":"JL Stamos","year":"2013","unstructured":"Stamos JL, Weis WI. The \u03b2-catenin destruction complex. Cold Spring Harb Perspect Biol. 2013;5:a007898.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"3425_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.canlet.2021.09.010","volume":"521","author":"Q Zuo","year":"2021","unstructured":"Zuo Q, Liao L, Yao Z-T, Liu Y-P, Wang D-K, Li S-J, Yin X-F, He Q-Y, Xu W-W. Targeting PP2A with lomitapide suppresses colorectal tumorigenesis through the activation of AMPK\/Beclin1-mediated autophagy. Cancer Lett. 2021;521:281\u201393.","journal-title":"Cancer Lett"},{"key":"3425_CR23","first-page":"107pp","volume-title":"Anti-cancer compositions and methods comprising Miriplatin assembled into ultrasmall Dot and\/or lomitapide","author":"C Yang","year":"2021","unstructured":"Yang C, Wang Z, Li Y. Anti-cancer compositions and methods comprising Miriplatin assembled into ultrasmall Dot and\/or lomitapide. Volume 107. USA: University of Kentucky Research Foundation; 2021. p. 107pp."},{"key":"3425_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.biomaterials.2018.10.019","volume":"188","author":"Y Li","year":"2019","unstructured":"Li Y, Xiao Y, Lin H-P, Reichel D, Bae Y, Lee EY, Jiang Y, Huang X, Yang C, Wang Z. In vivo \u03b2-catenin Attenuation by the integrin \u03b15-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis. Biomaterials. 2019;188:160\u201372.","journal-title":"Biomaterials"},{"key":"3425_CR25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jconrel.2016.06.012","volume":"240","author":"RX Zhang","year":"2016","unstructured":"Zhang RX, Wong HL, Xue HY, Eoh JY, Wu XY. Nanomedicine of synergistic drug combinations for cancer therapy\u2013Strategies and perspectives. J Controlled Release. 2016;240:489\u2013503.","journal-title":"J Controlled Release"},{"key":"3425_CR26","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.3390\/nano12152672","volume":"12","author":"RD Al Bostami","year":"2022","unstructured":"Al Bostami RD, Abuwatfa WH, Husseini GA. Recent advances in Nanoparticle-Based Co-Delivery systems for Cancer therapy. Nanomaterials. 2022;12:2672.","journal-title":"Nanomaterials"},{"key":"3425_CR27","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-020-2079-1","volume":"579","author":"Q Wang","year":"2020","unstructured":"Wang Q, Wang Y, Ding J, Wang C, Zhou X, Gao W, Huang H, Shao F, Liu Z. A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature. 2020;579:421\u20136.","journal-title":"Nature"},{"key":"3425_CR28","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.celrep.2016.05.071","volume":"16","author":"S-Y Hwang","year":"2016","unstructured":"Hwang S-Y, Deng X, Byun S, Lee C, Lee S-J, Suh H, Zhang J, Kang Q, Zhang T, Westover KD. Direct targeting of \u03b2-catenin by a small molecule stimulates proteasomal degradation and suppresses oncogenic Wnt\/\u03b2-catenin signaling. Cell Rep. 2016;16:28\u201336.","journal-title":"Cell Rep"},{"key":"3425_CR29","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3425_CR30","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1126\/science.275.5307.1790","volume":"275","author":"B Rubinfeld","year":"1997","unstructured":"Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science. 1997;275:1790\u20132.","journal-title":"Science"},{"key":"3425_CR31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/ijc.30040","volume":"139","author":"JP V\u00e4yrynen","year":"2016","unstructured":"V\u00e4yrynen JP, Kantola T, V\u00e4yrynen SA, Klintrup K, Bloigu R, Karhu T, M\u00e4kel\u00e4 J, Herzig KH, Karttunen TJ, Tuomisto A. The relationships between serum cytokine levels and tumor infiltrating immune cells and their clinical significance in colorectal cancer. Int J Cancer. 2016;139:112\u201321.","journal-title":"Int J Cancer"},{"key":"3425_CR32","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","volume":"9","author":"M Ruiz de Galarreta","year":"2019","unstructured":"Ruiz de Galarreta M, Bresnahan E, Molina-S\u00e1nchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, et al. \u03b2-Catenin activation promotes immune escape and resistance to Anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9:1124\u201341.","journal-title":"Cancer Discov"},{"key":"3425_CR33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17:20\u201337.","journal-title":"Nat Rev Cancer"},{"key":"3425_CR34","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1039\/D0TB02168G","volume":"9","author":"BG Carvalho","year":"2021","unstructured":"Carvalho BG, Vit FF, Carvalho HF, Han SW, Lucimara G. Recent advances in co-delivery nanosystems for synergistic action in cancer treatment. J Mater Chem B. 2021;9:1208\u201337.","journal-title":"J Mater Chem B"},{"key":"3425_CR35","doi-asserted-by":"publisher","first-page":"9273","DOI":"10.1007\/s00216-013-7300-8","volume":"405","author":"M Liu","year":"2013","unstructured":"Liu M, Ma X, Jin Z, Li W, Guo M, Li F. Determination and Pharmacokinetic study of the Diacid metabolite of Norcantharidin in beagle plasma by use of liquid chromatography\u2013tandem mass spectrometry. Anal Bioanal Chem. 2013;405:9273\u201383.","journal-title":"Anal Bioanal Chem"},{"key":"3425_CR36","unstructured":"[https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Lomitapide#section=Experimental-Properties]"},{"key":"3425_CR37","doi-asserted-by":"publisher","first-page":"5164","DOI":"10.1016\/j.bmc.2005.05.013","volume":"13","author":"Y Baba","year":"2005","unstructured":"Baba Y, Hirukawa N, Sodeoka M. Optically active Cantharidin analogues possessing selective inhibitory activity on Ser\/Thr protein phosphatase 2B (calcineurin): implications for the binding mode. Bioorg Med Chem. 2005;13:5164\u201370.","journal-title":"Bioorg Med Chem"},{"key":"3425_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrd2468","volume":"7","author":"J Rautio","year":"2008","unstructured":"Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, J\u00e4rvinen T, Savolainen J. Prodrugs: design and clinical applications. Nat Rev Drug Discovery. 2008;7:255\u201370.","journal-title":"Nat Rev Drug Discovery"},{"key":"3425_CR39","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nrc4027","volume":"15","author":"OC Olson","year":"2015","unstructured":"Olson OC, Joyce JA. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer. 2015;15:712\u201329.","journal-title":"Nat Rev Cancer"},{"key":"3425_CR40","doi-asserted-by":"crossref","unstructured":"Quijano-Rubio A, Bhuiyan AM, Yang H, Leung I, Bello E, Ali LR, Zhangxu K, Perkins J, Chun J-H, Wang W et al. A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy. Nat Biotechnol 2022;41:532-540.","DOI":"10.1038\/s41587-022-01510-z"},{"key":"3425_CR41","doi-asserted-by":"publisher","first-page":"eabc6424","DOI":"10.1126\/sciimmunol.abc6424","volume":"6","author":"Y Takeuchi","year":"2021","unstructured":"Takeuchi Y, Tanegashima T, Sato E, Irie T, Sai A, Itahashi K, Kumagai S, Tada Y, Togashi Y, Koyama S, et al. Highly Immunogenic cancer cells require activation of the WNT pathway for immunological escape. Sci Immunol. 2021;6:eabc6424.","journal-title":"Sci Immunol"},{"key":"3425_CR42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discovery. 2021;20:101\u201324.","journal-title":"Nat Rev Drug Discovery"},{"key":"3425_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2015.10.019","volume":"98","author":"JA Kemp","year":"2016","unstructured":"Kemp JA, Shim MS, Heo CY, Kwon YJ. Combo nanomedicine: co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Adv Drug Deliv Rev. 2016;98:3\u201318.","journal-title":"Adv Drug Deliv Rev"},{"key":"3425_CR44","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/s41586-023-05880-5","volume":"616","author":"J Hu","year":"2023","unstructured":"Hu J, S\u00e1nchez-Rivera FJ, Wang Z, Johnson GN, Ho Y-j, Ganesh K, Umeda S, Gan S, Mujal AM, Delconte RB. STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma. Nature. 2023;616:806\u201313.","journal-title":"Nature"},{"key":"3425_CR45","first-page":"370","volume-title":"Preparation of biphenyl compounds useful as immunomodulators for treatment of cancer, infectious diseases, and septic shock","author":"K-S Yeung","year":"2018","unstructured":"Yeung K-S, Grant-Young KA, Zhu J, Saulnier MG, Frennesson DB, Langley DR, Hewawasam P, Wang T, Zhang Z, Meng Z, et al. Preparation of biphenyl compounds useful as immunomodulators for treatment of cancer, infectious diseases, and septic shock. USA: Bristol-Myers Squibb Company; 2018. p. 370."},{"key":"3425_CR46","doi-asserted-by":"publisher","first-page":"106754","DOI":"10.1016\/j.bioorg.2023.106754","volume":"139","author":"X Feng","year":"2023","unstructured":"Feng X, Ge J, Fu H, Miao L, Zhao F, Wang J, Sun Y, Li Y, Li Y. Discovery of small molecule \u03b2-catenin suppressors that enhance immunotherapy. Bioorg Chem. 2023;139:106754.","journal-title":"Bioorg Chem"},{"key":"3425_CR47","doi-asserted-by":"crossref","unstructured":"Du L, Lee J-H, Jiang H, Wang C, Wang S, Zheng Z, Shao F, Xu D, Xia Y, Li J. \u03b2-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion. J Exp Med 2020;217:e20191115.","DOI":"10.1084\/jem.20191115"},{"key":"3425_CR48","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.ccell.2022.07.010","volume":"40","author":"D Lyden","year":"2022","unstructured":"Lyden D, Ghajar CM, Correia AL, Aguirre-Ghiso JA, Cai S, Rescigno M, Zhang P, Hu G, Fendt S-M, Boire A. Metastasis. Cancer Cell. 2022;40:787\u201391.","journal-title":"Cancer Cell"},{"key":"3425_CR49","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.trecan.2021.10.006","volume":"8","author":"PT de Lara","year":"2022","unstructured":"de Lara PT, Casta\u00f1\u00f3n H, Sterpi M, van den Broek M. Antimetastatic defense by CD8\u2009+\u2009T cells. Trends cancer. 2022;8:145\u201357.","journal-title":"Trends cancer"},{"key":"3425_CR50","doi-asserted-by":"publisher","first-page":"eaay1357","DOI":"10.1126\/sciadv.aay1357","volume":"5","author":"J-M Williford","year":"2019","unstructured":"Williford J-M, Ishihara J, Ishihara A, Mansurov A, Hosseinchi P, Marchell TM, Potin L, Swartz MA, Hubbell JA. Recruitment of CD103\u2009+\u2009dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy. Sci Adv. 2019;5:eaay1357.","journal-title":"Sci Adv"},{"key":"3425_CR51","doi-asserted-by":"publisher","first-page":"100672","DOI":"10.1016\/j.mtbio.2023.100672","volume":"20","author":"M Azizi","year":"2023","unstructured":"Azizi M, Jahanban-Esfahlan R, Samadian H, Hamidi M, Seidi K, Dolatshahi-Pirouz A, Yazdi AA, Shavandi A, Laurent S, Be Omide Hagh M, et al. Multifunctional nanostructures: intelligent design to overcome biological barriers. Mater Today Bio. 2023;20:100672.","journal-title":"Mater Today Bio"},{"key":"3425_CR52","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/s41467-020-14700-7","volume":"11","author":"A Fendler","year":"2020","unstructured":"Fendler A, Bauer D, Busch J, Jung K, Wulf-Goldenberg A, Kunz S, Song K, Myszczyszyn A, Elezkurtaj S, Erguen B. Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients. Nat Commun. 2020;11:929.","journal-title":"Nat Commun"},{"key":"3425_CR53","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.tibs.2018.06.003","volume":"43","author":"C Cui","year":"2018","unstructured":"Cui C, Zhou X, Zhang W, Qu Y, Ke X. Is \u03b2-catenin a druggable target for cancer therapy? Trends Biochem Sci. 2018;43:623\u201334.","journal-title":"Trends Biochem Sci"},{"key":"3425_CR54","doi-asserted-by":"publisher","first-page":"9170","DOI":"10.1038\/s41598-017-08971-2","volume":"7","author":"P Mukherjee","year":"2017","unstructured":"Mukherjee P, Gupta A, Chattopadhyay D, Chatterji U. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells. Sci Rep. 2017;7:9170.","journal-title":"Sci Rep"},{"key":"3425_CR55","doi-asserted-by":"publisher","first-page":"rv328324","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway Blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:rv328324\u2013328324.","journal-title":"Sci Transl Med"},{"key":"3425_CR56","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/jps.20100","volume":"93","author":"HL Wong","year":"2004","unstructured":"Wong HL, Bendayan R, Rauth AM, Wu XY. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci. 2004;93:1993\u20132008.","journal-title":"J Pharm Sci"},{"key":"3425_CR57","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jconrel.2006.09.007","volume":"116","author":"HL Wong","year":"2006","unstructured":"Wong HL, Bendayan R, Rauth AM, Wu XY. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Controlled Release. 2006;116:275\u201384.","journal-title":"J Controlled Release"},{"key":"3425_CR58","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10549-008-0271-3","volume":"119","author":"AJ Shuhendler","year":"2010","unstructured":"Shuhendler AJ, Cheung RY, Manias J, Connor A, Rauth AM, Wu XY. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res Treat. 2010;119:255\u201369.","journal-title":"Breast Cancer Res Treat"},{"key":"3425_CR59","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jconrel.2012.06.004","volume":"163","author":"H Xiao","year":"2012","unstructured":"Xiao H, Li W, Qi R, Yan L, Wang R, Liu S, Zheng Y, Xie Z, Huang Y, Jing X. Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy. J Controlled Release. 2012;163:304\u201314.","journal-title":"J Controlled Release"},{"key":"3425_CR60","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1158\/1535-7163.MCT-11-0987","volume":"11","author":"JR Hasenstein","year":"2012","unstructured":"Hasenstein JR, Shin H-C, Kasmerchak K, Buehler D, Kwon GS, Kozak KR. Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG. Mol Cancer Ther. 2012;11:2233\u201342.","journal-title":"Mol Cancer Ther"},{"key":"3425_CR61","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.1002\/jcp.26265","volume":"233","author":"M Majidinia","year":"2018","unstructured":"Majidinia M, Aghazadeh J, Jahanban-Esfahlani R, Yousefi B. The roles of Wnt\/\u03b2-catenin pathway in tissue development and regenerative medicine. J Cell Physiol. 2018;233:5598\u2013612.","journal-title":"J Cell Physiol"},{"key":"3425_CR62","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2021.10.034","volume":"525","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Xu J, Luo H, Meng X, Chen M, Zhu D. Wnt signaling pathway in cancer immunotherapy. Cancer Lett. 2022;525:84\u201396.","journal-title":"Cancer Lett"},{"key":"3425_CR63","doi-asserted-by":"publisher","first-page":"a028472","DOI":"10.1101\/cshperspect.a028472","volume":"10","author":"TA Waldmann","year":"2018","unstructured":"Waldmann TA. Cytokines in cancer immunotherapy. Cold Spring Harb Perspect Biol. 2018;10:a028472.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"3425_CR64","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jconrel.2020.10.015","volume":"329","author":"Y Li","year":"2021","unstructured":"Li Y, Qian D, Lin H-P, Xie J, Yang P, Maddy D, Xiao Y, Huang X, Wang Z, Yang C. Nanoparticle-delivered Miriplatin ultrasmall Dots suppress triple negative breast cancer lung metastasis by targeting Circulating tumor cells. J Controlled Release. 2021;329:833\u201346.","journal-title":"J Controlled Release"},{"key":"3425_CR65","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cell.2006.09.025","volume":"127","author":"Y Xing","year":"2006","unstructured":"Xing Y, Xu Y, Chen Y, Jeffrey PD, Chao Y, Lin Z, Li Z, Strack S, Stock JB, Shi Y. Structure of protein phosphatase 2A core enzyme bound to tumor-inducing toxins. Cell. 2006;127:341\u201353.","journal-title":"Cell"},{"key":"3425_CR66","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.bbrc.2023.01.033","volume":"646","author":"H Sitosari","year":"2023","unstructured":"Sitosari H, Morimoto I, Weng Y, Zheng Y, Fukuhara Y, Ikegame M, Okamura H. Inhibition of protein phosphatase 2A by Okadaic acid induces translocation of nucleocytoplasmic O-GlcNAc transferase. Biochem Biophys Res Commun. 2023;646:50\u20135.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03425-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03425-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03425-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T14:03:49Z","timestamp":1747836229000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03425-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3425"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03425-8","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental protocol concerning animals used in this work was approved by the Animal Ethical Committee at Tianjin University of Traditional Chinese Medicine and adhered to the animal care guidelines of Laboratory Animal Management Committee (Approval TCM-LAEC2023114).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors involved in this study have provided their consent for the publication of the research findings.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"369"}}